

November 2nd, 2021

COM-2021-051

Dear provider of healthcare-related services,

On October 29th, 2021 the U.S. Food and Drug Administration authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include children 5 through 11 years of age. The FDA has determined this vaccine has met the criteria for emergency use authorization. The known and potential benefits of the vaccine in this population outweigh the known and potential risks.

The Pfizer-BioNTech COVID-19 vaccine for this population is administered as a two-dose primary series, 3 weeks apart, but is a lower dose (10 micrograms) than that used for individuals 12 years of age and older (30 micrograms). Immune responses of children 5 through 11 years of age were comparable to those of individuals 16 through 25 years of age. In addition, the vaccine was found to be 90.7% effective in preventing COVID-19 in children 5 through 11. The vaccine's safety was studied in approximately 3,100 children aged 5 through 11 who received the vaccine and no serious side effects have been detected in the ongoing study. The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) now recommends the Pfizer-BioNTech COVID-19 vaccine for children between the ages of 5 to 11.

For additional information, you can refer to:

1. [EUA fact sheet of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019](#)
2. [FDA news release](#)

The situation with the COVID-19 pandemic is dynamic and constantly changing. We strongly encourage the frequent revision of updated information provided by the FDA, the Centers for Disease and Control Prevention (CDC), and the World Health Organization (WHO), to assure that your practices are consistent with the most updated information.

PharmPix is committed to the health and wellness of our members, and to support you as the COVID-19 pandemic continues to evolve. It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252, extension 220.

Kind regards,

Clinical Department